Global Biosimilar Testing Service 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI12242073

Publication Date:

December 4, 2024

Pages:

118

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Biosimilar Testing Service market size was valued at US$ million in 2023. With growing demand in downstream market, the Biosimilar Testing Service is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Biosimilar Testing Service market. Biosimilar Testing Service are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Biosimilar Testing Service. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Biosimilar Testing Service market.
Biosimilar are the biological based products used for various use in healthcare industry. Biosimilar products are very helpful to the patients and also offer therapeutic options. Biosimilar have a unique properties, which is used to study the biological functions and structures complexity of the sample.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Biosimilar Testing Service market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Biosimilar Testing Service market. It may include historical data, market segmentation by Type (e.g., Pharmacokinetic Assay, Tiered Immunogenicity Testing), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Biosimilar Testing Service market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Biosimilar Testing Service market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Biosimilar Testing Service industry. This include advancements in Biosimilar Testing Service technology, Biosimilar Testing Service new entrants, Biosimilar Testing Service new investment, and other innovations that are shaping the future of Biosimilar Testing Service.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Biosimilar Testing Service market. It includes factors influencing customer ' purchasing decisions, preferences for Biosimilar Testing Service product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Biosimilar Testing Service market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Biosimilar Testing Service market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Biosimilar Testing Service market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Biosimilar Testing Service industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Biosimilar Testing Service market.
麻豆原创 Segmentation:
Biosimilar Testing Service market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Pharmacokinetic Assay
Tiered Immunogenicity Testing
Others
Segmentation by application
Hospitals
Pharmaceutical Companies
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Charles River Laboratories International
Merck
PPD
LAB Holdings
Eurofins Scientific
Intertek
SGS
Profacgen
Antibody Analytics
Kymos Pharma Services
Medicilon
Pacific BioLabs
Sartorius

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Biosimilar Testing Service 麻豆原创 Size 2019-2030
2.1.2 Biosimilar Testing Service 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Biosimilar Testing Service Segment by Type
2.2.1 Pharmacokinetic Assay
2.2.2 Tiered Immunogenicity Testing
2.2.3 Others
2.3 Biosimilar Testing Service 麻豆原创 Size by Type
2.3.1 Biosimilar Testing Service 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Biosimilar Testing Service 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Biosimilar Testing Service Segment by Application
2.4.1 Hospitals
2.4.2 Pharmaceutical Companies
2.4.3 Others
2.5 Biosimilar Testing Service 麻豆原创 Size by Application
2.5.1 Biosimilar Testing Service 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Biosimilar Testing Service 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Biosimilar Testing Service 麻豆原创 Size by Player
3.1 Biosimilar Testing Service 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Biosimilar Testing Service Revenue by Players (2019-2024)
3.1.2 Global Biosimilar Testing Service Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Biosimilar Testing Service Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Biosimilar Testing Service by Regions
4.1 Biosimilar Testing Service 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Biosimilar Testing Service 麻豆原创 Size Growth (2019-2024)
4.3 APAC Biosimilar Testing Service 麻豆原创 Size Growth (2019-2024)
4.4 Europe Biosimilar Testing Service 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Biosimilar Testing Service 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Biosimilar Testing Service 麻豆原创 Size by Country (2019-2024)
5.2 Americas Biosimilar Testing Service 麻豆原创 Size by Type (2019-2024)
5.3 Americas Biosimilar Testing Service 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biosimilar Testing Service 麻豆原创 Size by Region (2019-2024)
6.2 APAC Biosimilar Testing Service 麻豆原创 Size by Type (2019-2024)
6.3 APAC Biosimilar Testing Service 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Biosimilar Testing Service by Country (2019-2024)
7.2 Europe Biosimilar Testing Service 麻豆原创 Size by Type (2019-2024)
7.3 Europe Biosimilar Testing Service 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Biosimilar Testing Service by Region (2019-2024)
8.2 Middle East & Africa Biosimilar Testing Service 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Biosimilar Testing Service 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Biosimilar Testing Service 麻豆原创 Forecast
10.1 Global Biosimilar Testing Service Forecast by Regions (2025-2030)
10.1.1 Global Biosimilar Testing Service Forecast by Regions (2025-2030)
10.1.2 Americas Biosimilar Testing Service Forecast
10.1.3 APAC Biosimilar Testing Service Forecast
10.1.4 Europe Biosimilar Testing Service Forecast
10.1.5 Middle East & Africa Biosimilar Testing Service Forecast
10.2 Americas Biosimilar Testing Service Forecast by Country (2025-2030)
10.2.1 United States Biosimilar Testing Service 麻豆原创 Forecast
10.2.2 Canada Biosimilar Testing Service 麻豆原创 Forecast
10.2.3 Mexico Biosimilar Testing Service 麻豆原创 Forecast
10.2.4 Brazil Biosimilar Testing Service 麻豆原创 Forecast
10.3 APAC Biosimilar Testing Service Forecast by Region (2025-2030)
10.3.1 China Biosimilar Testing Service 麻豆原创 Forecast
10.3.2 Japan Biosimilar Testing Service 麻豆原创 Forecast
10.3.3 Korea Biosimilar Testing Service 麻豆原创 Forecast
10.3.4 Southeast Asia Biosimilar Testing Service 麻豆原创 Forecast
10.3.5 India Biosimilar Testing Service 麻豆原创 Forecast
10.3.6 Australia Biosimilar Testing Service 麻豆原创 Forecast
10.4 Europe Biosimilar Testing Service Forecast by Country (2025-2030)
10.4.1 Germany Biosimilar Testing Service 麻豆原创 Forecast
10.4.2 France Biosimilar Testing Service 麻豆原创 Forecast
10.4.3 UK Biosimilar Testing Service 麻豆原创 Forecast
10.4.4 Italy Biosimilar Testing Service 麻豆原创 Forecast
10.4.5 Russia Biosimilar Testing Service 麻豆原创 Forecast
10.5 Middle East & Africa Biosimilar Testing Service Forecast by Region (2025-2030)
10.5.1 Egypt Biosimilar Testing Service 麻豆原创 Forecast
10.5.2 South Africa Biosimilar Testing Service 麻豆原创 Forecast
10.5.3 Israel Biosimilar Testing Service 麻豆原创 Forecast
10.5.4 Turkey Biosimilar Testing Service 麻豆原创 Forecast
10.5.5 GCC Countries Biosimilar Testing Service 麻豆原创 Forecast
10.6 Global Biosimilar Testing Service Forecast by Type (2025-2030)
10.7 Global Biosimilar Testing Service Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Charles River Laboratories International
11.1.1 Charles River Laboratories International Company Information
11.1.2 Charles River Laboratories International Biosimilar Testing Service Product Offered
11.1.3 Charles River Laboratories International Biosimilar Testing Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Charles River Laboratories International Main Business Overview
11.1.5 Charles River Laboratories International Latest Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Biosimilar Testing Service Product Offered
11.2.3 Merck Biosimilar Testing Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Merck Main Business Overview
11.2.5 Merck Latest Developments
11.3 PPD
11.3.1 PPD Company Information
11.3.2 PPD Biosimilar Testing Service Product Offered
11.3.3 PPD Biosimilar Testing Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 PPD Main Business Overview
11.3.5 PPD Latest Developments
11.4 LAB Holdings
11.4.1 LAB Holdings Company Information
11.4.2 LAB Holdings Biosimilar Testing Service Product Offered
11.4.3 LAB Holdings Biosimilar Testing Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 LAB Holdings Main Business Overview
11.4.5 LAB Holdings Latest Developments
11.5 Eurofins Scientific
11.5.1 Eurofins Scientific Company Information
11.5.2 Eurofins Scientific Biosimilar Testing Service Product Offered
11.5.3 Eurofins Scientific Biosimilar Testing Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Eurofins Scientific Main Business Overview
11.5.5 Eurofins Scientific Latest Developments
11.6 Intertek
11.6.1 Intertek Company Information
11.6.2 Intertek Biosimilar Testing Service Product Offered
11.6.3 Intertek Biosimilar Testing Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Intertek Main Business Overview
11.6.5 Intertek Latest Developments
11.7 SGS
11.7.1 SGS Company Information
11.7.2 SGS Biosimilar Testing Service Product Offered
11.7.3 SGS Biosimilar Testing Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 SGS Main Business Overview
11.7.5 SGS Latest Developments
11.8 Profacgen
11.8.1 Profacgen Company Information
11.8.2 Profacgen Biosimilar Testing Service Product Offered
11.8.3 Profacgen Biosimilar Testing Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Profacgen Main Business Overview
11.8.5 Profacgen Latest Developments
11.9 Antibody Analytics
11.9.1 Antibody Analytics Company Information
11.9.2 Antibody Analytics Biosimilar Testing Service Product Offered
11.9.3 Antibody Analytics Biosimilar Testing Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Antibody Analytics Main Business Overview
11.9.5 Antibody Analytics Latest Developments
11.10 Kymos Pharma Services
11.10.1 Kymos Pharma Services Company Information
11.10.2 Kymos Pharma Services Biosimilar Testing Service Product Offered
11.10.3 Kymos Pharma Services Biosimilar Testing Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Kymos Pharma Services Main Business Overview
11.10.5 Kymos Pharma Services Latest Developments
11.11 Medicilon
11.11.1 Medicilon Company Information
11.11.2 Medicilon Biosimilar Testing Service Product Offered
11.11.3 Medicilon Biosimilar Testing Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Medicilon Main Business Overview
11.11.5 Medicilon Latest Developments
11.12 Pacific BioLabs
11.12.1 Pacific BioLabs Company Information
11.12.2 Pacific BioLabs Biosimilar Testing Service Product Offered
11.12.3 Pacific BioLabs Biosimilar Testing Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Pacific BioLabs Main Business Overview
11.12.5 Pacific BioLabs Latest Developments
11.13 Sartorius
11.13.1 Sartorius Company Information
11.13.2 Sartorius Biosimilar Testing Service Product Offered
11.13.3 Sartorius Biosimilar Testing Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Sartorius Main Business Overview
11.13.5 Sartorius Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.